Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
|Articles|December 14, 2021
Daily Medication Pearl: Gabapentin Enacarbil (Horizant)
Author(s)Saro Arakelians, PharmD
Gabapentin enacarbil treats moderate-to-severe primary restless leg syndrome and postherpetic neuralgia.
Advertisement
Medication Pearl of the Day: Gabapentin Enacarbil (Horizant)
Indication: Gabapentin enacarbil is indicated for the treatment of moderate-to-severe primary restless legs syndrome (RLS) in adults and the management of postherpetic neuralgia (PHN) in adults.
Insight:
- Dosing: For RLS, 600 mg once daily taken at about 5 pm. A dose of 1200 mg once daily provided no additional benefit compared with the 600-mg dose, but caused an increase in adverse reactions.
- Dosage forms: Extended-release tablets 300 mg and 600 mg.
- Adverse events (AEs): Most common AEs (≥10% and at least 2 times the rate of placebo) were somnolence/sedation and dizziness.
- Mechanism of action: Gabapentin prevents pain-related responses in several models of neuropathic pain in humans.
- Manufacturer: Arbor Pharmaceuticals
Sources:
Advertisement
Related to this article
In a Pharmacy Times interview, study coauthor William J. Peppard, PharmD, discusses the association between suzetrigine and fewer opioid refills after knee replacement, the limits of the evidence, and the access barriers pharmacists can help patients navigate.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Hemoglobin, platelets, bleeding, pericardial effusions, and intrapulmonary shunting top the monitoring list for patients with pulmonary arterial hypertension (PAH) starting with sotatercept, according to Vallerie McLaughlin, MD.
Marie-Claire Seeley, RN, MNurs, PhD, discusses standing tests, medication review, and what inflammatory findings may mean for future POTS treatment.
FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.
A single infusion reversed new-onset type 1 diabetes (T1D) in more than half of treated mice by strengthening regulatory T cells and driving autoreactive CD8+ T cells into a less destructive state.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tavapadon, First D1/D5 Agonist for Parkinson Disease
2
FDA Approves Tiratricol, First Treatment for MCT8 Deficiency
3
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
4
Expert Q&A: Researcher Urges Autonomic Assessment for Patients With Long COVID
5